The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Dual immune checkpoint inhibition in advanced incurable radioidine-refractory differentiated thyroid carcinoma (RAIR DTC), anaplastic (ATC), and medullary thyroid carcinoma (MTC): Long-term survival results from phase II clinical trial.
 
Kartik Sehgal
Honoraria - Academy for Continued Healthcare Learning; AmerisourceBergen; Binacea; Medscape; Pri-Med
Consulting or Advisory Role - Equinox Group; Exelixis; Guidepoint Global; Medscape; Pfizer; Scholar Rock
Research Funding - Merck (Inst)
Travel, Accommodations, Expenses - Binacea; Merck; Pfizer; Pri-Med
 
Theodora Pappa
Employment - Deciphera (I); Replimune (I)
Stock and Other Ownership Interests - Abbott Laboratories (I); Abbvie (I); Deciphera (I); Replimune (I)
 
Kee-Young Shin
No Relationships to Disclose
 
Mofei Liu
No Relationships to Disclose
 
Kathleen Pfaff
Employment - Dana-Farber Cancer Institute
Patents, Royalties, Other Intellectual Property - receive royalties for patent on a high content screening assay for iPSC-derived motor neuron survival (work done prior to joining DFCI)
 
Justine Barletta
No Relationships to Disclose
 
Gerard Doherty
No Relationships to Disclose
 
Erik Alexander
Honoraria - Pink Dx; Roche Diagnostics Solutions; Veracyte
 
Scott Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead Company; Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
Glenn Hanna
Employment - Dana-Farber Cancer Institute
Honoraria - Massachusetts Medical Society
Consulting or Advisory Role - Bicara Therapeutics; Boxer Capital; Bristol-Myers Squibb; Coherus Biosciences; Coherus Biosciences; Elevar Therapeutics; Grey Wolf Therapeutics; InhibRx; KSQ Therapeutics; Kura Oncology; Merck; Naveris; Nextech Invest; PDS Biotechnology; Remix Therapeutics; Replimune; Surface Oncology
Research Funding - Actuate Therapeutics (Inst); Adenoid Cystic Carcinoma Research Foundation (Inst); ASCO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); Gateway for Cancer Research; Genentech (Inst); ImmunityBio (Inst); Kura Oncology (Inst); Regeneron (Inst); Secura Bio (Inst)
 
David Barbie
Stock and Other Ownership Interests - Medzown; Xsphera Biosciences
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Gilead Sciences; Synthekine
Consulting or Advisory Role - Nerviano Medical Sciences; Qiagen/N of One
Research Funding - Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Gilead Sciences; Novartis
Patents, Royalties, Other Intellectual Property - DFCI patents on microfluidic culture and analysis of organotypic tumor spheroids
 
Anne ONeill
No Relationships to Disclose
 
Eliezer Van Allen
Stock and Other Ownership Interests - ervaxx; Genome Medical; Genomic Life; Manifold Bio; Microsoft; Monte Rosa Therapeutics; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics
Consulting or Advisory Role - ervaxx; Genome Medical; Genomic Life; Illumina; Janssen; Manifold Bio; Monte Rosa Therapeutics; Novartis; Riva Therapeutics; Serinus Bio; Syapse; Tango Therapeutics; Tracer Bio
Speakers' Bureau - Illumina; TD Cowen
Research Funding - Bristol-Myers Squibb; Nextpoint (Inst); Novartis; Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Patent on clinical interpretation algorithms using cancer molecular data (Inst); Patent on discovery of chromatin regulators as biomarkers of response to cancer immunotherapy (Inst); Patent on discovery of retained intron as source of cancer neoantigens (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Robert Haddad
Employment - Dana-Farber Cancer Institute
Leadership - NCCN
Stock and Other Ownership Interests - tosk
Consulting or Advisory Role - ALX Oncology; AstraZeneca; aveo; Bayer; Boehringer Ingelheim; Eisai; EMD Serono; Genmab; Genzyme; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; PDS Biotechnology; Scholar Rock
Research Funding - AstraZeneca (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst); Merus (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Boehringer Ingelheim; Hookipa Pharma; ISA Pharmaceuticals; Nanobiotix
 
Jochen Lorch
Honoraria - Adlai Norteye; Bayer
Consulting or Advisory Role - Bayer; Eisai; Genentech; Novartis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Millenium Pharamceuticals (Inst)